Journal of Materials Science

, Volume 54, Issue 1, pp 745–764 | Cite as

Synthesis of polyphosphazene and preparation of microspheres from polyphosphazene blends with PMMA for drug combination therapy

  • Raja Summe Ullah
  • Li Wang
  • Haojie Yu
  • Muhammad Haroon
  • Tarig Elshaarani
  • Kaleem-ur-Rahman Naveed
  • Shah Fahad
  • Amin Khan
  • Ahsan Nazir
  • Xia Xia
  • Lisong Teng
Materials for life sciences


Drug combination therapy is an emerging technology to treat the diseases which are still annoyance to human being. Combination of two or more drugs can deal with diseases in a better way. Various different techniques have been introduced which can deliver combination of drugs in a safe and more controlled manner. In our research, we prepared polyphosphazene-based blend microspheres which can deliver two different drugs in a much sustained manner for long time. “Acetamidophenol,” commonly used drug, was attached to the polyphosphazene main chain to produce drug–polymer conjugates, and these were then blended with PMMA in different ratios to fabricate the microspheres of variable and controlled size. Another anticancer drug “camptothecin” was loaded in these microspheres to fabricate dual-drug-loaded microsphere. Furthermore, in vitro drug release behaviors of fabricated microspheres were also demonstrated.


  1. 1.
    Mullard A (2015) FDA drug approvals. Nat Rev Drug Discov 15(2016):73–76Google Scholar
  2. 2.
    Qi J, Zhang Y, Gou Y, Lee P, Wang J, Chen S, Zhou Z, Wu X, Yang F, Liang H (2016) Multidrug delivery systems based on human serum albumin for combination therapy with three anticancer agents. Mol Pharm 13:3098–3105CrossRefGoogle Scholar
  3. 3.
    Zhao L, Zhu L, Liu F, Liu C, Shan D, Wang Q, Zhang C, Li J, Liu J, Qu X, Yang Z (2011) pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel. Int J Pharm 410:83–91CrossRefGoogle Scholar
  4. 4.
    Wang H, Wu J, Xie K, Fang T, Chen C, Xie H, Zhou L, Zheng S (2017) Precise engineering of prodrug cocktails into single polymeric nanoparticles for combination cancer therapy: extended and sequentially controllable drug release. ACS Appl Mater Interfaces 9:10567–10576CrossRefGoogle Scholar
  5. 5.
    Kumar P, Lakshmi YS, Kondapi AK (2017) Triple drug combination of zidovudine, efavirenz and lamivudine loaded lactoferrin nanoparticles: an effective nano first-line regimen for HIV therapy. Pharm Res 34:257–268CrossRefGoogle Scholar
  6. 6.
    de Oliveira VA, da Motta LL, De Bastiani MA, Lopes FM, Muller CB, Gabiatti BP, Franca FS, Alves Castro MA, Klamt F (2016) In vitro evaluation of antitumoral efficacy of catalase in combination with traditional chemotherapeutic drugs against human lung adenocarcinoma cells. Tumor Biol 37:10775–10784CrossRefGoogle Scholar
  7. 7.
    Conde J, Oliva N, Zhang Y, Artzi N (2016) Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. Nat Mater 15:1128–1138CrossRefGoogle Scholar
  8. 8.
    Grayson ACR, Choi IS, Tyler BM, Wang PP, Brem H, Cima MJ, Langer R (2003) Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater 2:767–772CrossRefGoogle Scholar
  9. 9.
    Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, Hanna TN, Liu J, Phillips B, Carter MB, Carroll NJ, Jiang X, Dunphy DR, Willman CL, Petsev DN, Evans DG, Parikh AN, Chackerian B, Wharton W, Peabody DS, Brinker CJ (2011) The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 10:389–397CrossRefGoogle Scholar
  10. 10.
    Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, Jay SM, Demento SL, Agawu A, Limon PL, Ferrandino AF, Gonzalez D, Habermann A, Flavell RA, Fahmy TM (2012) Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater 11:895–905CrossRefGoogle Scholar
  11. 11.
    Sun W, Sanderson PE, Zheng W (2016) Drug combination therapy increases successful drug repositioning. Drug Discov Today 21:1189–1195CrossRefGoogle Scholar
  12. 12.
    Csermely P, Ágoston V, Pongor S (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26:178–182CrossRefGoogle Scholar
  13. 13.
    Dong X, Chen H, Qin J, Wei C, Liang J, Liu T, Kong D, Lv F (2017) Thermosensitive porphyrin-incorporated hydrogel with four-arm PEG-PCL copolymer (II): doxorubicin loaded hydrogel as a dual fluorescent drug delivery system for simultaneous imaging tracking in vivo. Drug Deliv 24:641–650CrossRefGoogle Scholar
  14. 14.
    Dong Z, Feng L, Zhu W, Sun X, Gao M, Zhao H, Chao Y, Liu Z (2016) CaCO3 nanoparticles as an ultra-sensitive tumor-pH-responsive nanoplatform enabling real-time drug release monitoring and cancer combination therapy. Biomaterials 110:60–70CrossRefGoogle Scholar
  15. 15.
    Patel B, Rashid J, Gupta N, Ahsan F (2017) Low-molecular-weight heparin-coated and montelukast-filled inhalable particles: a dual-drug delivery system for combination therapy in asthma. J Pharm Sci 106:1124–1135CrossRefGoogle Scholar
  16. 16.
    Calabresi PA (2004) Diagnosis and management of multiple sclerosis. Am Fam Phys 70:1935–1944Google Scholar
  17. 17.
    Friese MA, Schattling B, Fugger L (2014) Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 10:225–238CrossRefGoogle Scholar
  18. 18.
    Zeynabad FB, Salehi R, Mahkam M (2017) Design of pH-responsive antimicrobial nanocomposite as dual drug delivery system for tumor therapy. Appl Clay Sci 141:23–35CrossRefGoogle Scholar
  19. 19.
    Eitan E, Hutchison ER, Greig NH, Tweedie D, Celik H, Ghosh S, Fishbein KW, Spencer RG, Sasaki CY, Ghosh P, Das S, Chigurapati S, Raymick J, Sarkar S, Chigurupati S, Seal S, Mattson MP (2015) Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. Exp Neurol 273:151–160CrossRefGoogle Scholar
  20. 20.
    Rawat M, Singh D, Saraf S, Saraf S (2006) Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull 29:1790–1798CrossRefGoogle Scholar
  21. 21.
    Wang X, Yang L, Chen Z, Shin DM (2008) Application of nanotechnology in cancer therapy and imaging. CA-Cancer J Clin 58:97–110CrossRefGoogle Scholar
  22. 22.
    Yang J, Lee C-H, Park J, Seo S, Lim E-K, Song YJ, Suh J-S, Yoon H-G, Huh Y-M, Haam S (2007) Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J Mater Chem 17:2695–2699CrossRefGoogle Scholar
  23. 23.
    Vaage J, Mayhew E, Lasic D, Martin F (1992) Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer 51:942–948CrossRefGoogle Scholar
  24. 24.
    Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E, TDS Group (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25–36CrossRefGoogle Scholar
  25. 25.
    Hu F-Q, Liu L-N, Du Y-Z, Yuan H (2009) Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomaterials 30:6955–6963CrossRefGoogle Scholar
  26. 26.
    Yoo HS, Park TG (2001) Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA–PEG block copolymer. J Controlled Release 70:63–70CrossRefGoogle Scholar
  27. 27.
    Xu X, Chen X, Ma PA, Wang X, Jing X (2008) The release behavior of doxorubicin hydrochloride from medicated fibers prepared by emulsion-electrospinning. Eur J Pharm Biopharm 70:165–170CrossRefGoogle Scholar
  28. 28.
    Khandare J, Minko T (2006) Polymer–drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 31:359–397CrossRefGoogle Scholar
  29. 29.
    Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R, Farokhzad OC (2010) Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 107:17939–17944CrossRefGoogle Scholar
  30. 30.
    Aryal S, Hu C-MJ, Zhang L (2010) Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small 6:1442–1448CrossRefGoogle Scholar
  31. 31.
    Zhang L, Moreno AFR, Alexis F, Gu FX, Basto PA, Bagalkot V, Jon S, Langer RS, Farokhzad OC (2007) Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle–aptamer bioconjugates. ChemMedChem 2:1268–1271CrossRefGoogle Scholar
  32. 32.
    Aryal S, Hu C-MJ, Zhang L (2011) Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm 8:1401–1407CrossRefGoogle Scholar
  33. 33.
    Wang Z, Ho PC (2010) A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 31:7115–7123CrossRefGoogle Scholar
  34. 34.
    Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436:568–572CrossRefGoogle Scholar
  35. 35.
    Li C, Wallace S (2008) Polymer-drug conjugates: recent development in clinical oncology. Adv. Drug Deliver. Rev. 60:886–898CrossRefGoogle Scholar
  36. 36.
    Ullah RS, Wang L, Yu H, Abbasi NM, Akram M, Ul-Abdin Z, Saleem M, Haroon M, Khan RU (2017) Synthesis of polyphosphazenes with different side groups and various tactics for drug delivery. RSC Adv 7:23363–23391CrossRefGoogle Scholar
  37. 37.
    Morozowich NL, Nichol JL, Mondschein RJ, Allcock HR (2012) Design and examination of an antioxidant-containing polyphosphazene scaffold for tissue engineering. Polym Chem 3:778–786CrossRefGoogle Scholar
  38. 38.
    Cho SY, Allcock HR (2007) Dendrimers derived from polyphosphazene-poly(propyleneimine) systems: encapsulation and triggered release of hydrophobic guest molecules. Macromolecules 40:3115–3121CrossRefGoogle Scholar
  39. 39.
    Hidaka K, Moine L, Collin G, Labarre D, Louis Grossiord J, Huang N, Osuga K, Wada S, Laurent A (2011) Elasticity and viscoelasticity of embolization microspheres. J Mech Behav Biomed Mater 4:2161–2167CrossRefGoogle Scholar
  40. 40.
    Sethuraman S, Nair LS, El-Amin S, Nguyen M-T, Singh A, Krogman N, Greish YE, Allcock HR, Brown PW, Laurencin CT (2010) Mechanical properties and osteocompatibility of novel biodegradable alanine based polyphosphazenes: side group effects. Acta Biomater 6:1931–1937CrossRefGoogle Scholar
  41. 41.
    Babu M, Yadav HKS, Moin A, Shivakumar HG (2011) In vitro–in vivo evaluation of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel implants containing cisplatin. Acta Pharm Sin B 1:261–267CrossRefGoogle Scholar
  42. 42.
    Altinoz MA, Korkmaz R (2004) NF-kappa B, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 51:239–247Google Scholar
  43. 43.
    García Rodríguez LA, González-Pérez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 91:525CrossRefGoogle Scholar
  44. 44.
    Zhang JX, Qiu LY, Jin Y, Zhu KJ (2005) Physicochemical characterization of polymeric micelles constructed from novel amphiphilic polyphosphazene with poly(N-isopropylacrylamide) and ethyl 4-aminobenzoate as side groups. Colloids Surf B-Biointerfaces 43:123–130CrossRefGoogle Scholar
  45. 45.
    Sohn YS, Cho YH, Baek H, Jung O-S (1995) Synthesis and properties of low molecular weight polyphosphazenes. Macromolecules 28:7566–7568CrossRefGoogle Scholar
  46. 46.
    Akram M, Yu H, Wang L, Khalid H, Abbasi NM, Zain Ul A, Chen Y, Ren F, Saleem M (2016) Sustained release of hydrophilic drug from polyphosphazenes/poly(methyl methacrylate) based microspheres and their degradation study. Mater Sci Eng C-Mater Biol Appl 58:169–179CrossRefGoogle Scholar
  47. 47.
    Gao M, Zhu X, Wu L, Qiu L (2016) Cationic polyphosphazene vesicles for cancer immunotherapy by efficient in vivo cytokine IL-12 plasmid delivery. Biomacromol 17:2199–2209CrossRefGoogle Scholar
  48. 48.
    Rothemund S, Aigner TB, Iturmendi A, Rigau M, Husár B, Hildner F, Oberbauer E, Prambauer M, Olawale G, Forstner R (2015) Degradable glycine-based photo-polymerizable polyphosphazenes for use as scaffolds for tissue regeneration. Macromol Biosci 15:351–363CrossRefGoogle Scholar
  49. 49.
    Valenzuela ML, Carriedo GA (2011) Poly-dioxybiphenyl phosphazene random copolymers with pendant 3-hydroxy-propyl groups and polycaprolactone branches. Polymer 52:2157–2162CrossRefGoogle Scholar
  50. 50.
    Veronese FM, Marsilio F, Caliceti P, De Filippis P, Giunchedi P, Lora S (1998) Polyorganophosphazene microspheres for drug release: polymer synthesis, microsphere preparation, in vitro and in vivo naproxen release. J Controlled Release 52:227–237CrossRefGoogle Scholar
  51. 51.
    Allcock HR, Morozowich NL (2012) Bioerodible polyphosphazenes and their medical potential. Polym Chem 3:578–590CrossRefGoogle Scholar
  52. 52.
    Shen Y, Jin E, Zhang B, Murphy CJ, Sui M, Zhao J, Wang J, Tang J, Fan M, Van Kirk E, Murdoch WJ (2010) Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery. J Am Chem Soc 132:4259–4265CrossRefGoogle Scholar
  53. 53.
    Liu XP, Zhou ST, Li XY, Chen XC, Zhao X, Qian ZY, Zhou LN, Li ZY, Wang YM, Zhong Q, Yi T, Li ZY, He X, Wei YQ (2010) Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model. J. Exp. Clin. Canc. Res. 29:76CrossRefGoogle Scholar
  54. 54.
    Wang LM, Li QY, Zu YG, Fu YJ, Chen LY, Lv HY, Yao LP, Jiang SG (2008) Anti-proliferative and pro-apoptotic effect of CPT13, a novel camptothecin analog, on human colon cancer HCT8 cell line. Chem-Biol Interact 176:165–172CrossRefGoogle Scholar
  55. 55.
    Van Hattum AH, Pinedo HM, Schluper HM, Erkelens CA, Tohgo A, Boven E (2002) The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochem Pharmacol 64:1267–1277CrossRefGoogle Scholar
  56. 56.
    Knight V, Koshkina MV, Waldrep JC, Giovanella BC, Gilbert BE (1999) Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 44:177–186CrossRefGoogle Scholar
  57. 57.
    Lee DH, Kim SW, Suh C, Lee JS, Lee JH, Lee SJ, Ryoo BY, Park K, Kim JS, Heo DS, Kim NK (2008) Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 19:123–127CrossRefGoogle Scholar
  58. 58.
    Friis S, Nielsen GL, Mellemkjaer L, McLaughlin JK, Thulstrup AM, Blot WJ, Lipworth L, Vilstrup H, Olsen JH (2002) Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 97:96–101CrossRefGoogle Scholar
  59. 59.
    Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE (2002) Aspirin, other NSAIDs, and ovarian cancer risk (United States), Cancer Cause. Control 13:535–542Google Scholar
  60. 60.
    Cramer DW, Liberman RF, Hornstein MD, McShane P, Powers D, Li EY, Barbieri R (1998) Basal hormone levels in women who use acetaminophen for menstrual pain. Fertil Steril 70:371–373CrossRefGoogle Scholar
  61. 61.
    Akram M, Wang L, Yu H, Khalid H, Abbasi NM, Ul-Abdin Z, Chen Y, Sun R, Jie S, Saleem M (2016) Synthesis of reductive responsive polyphosphazenes and their fabrication of nanocarriers for drug delivery application. Int J Polym Mater Polym Biomater 65:581–591CrossRefGoogle Scholar
  62. 62.
    Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, Okano T (2004) Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm Res 21:2001–2008CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.State Key Laboratory of Chemical Engineering, College of Chemical and Biological EngineeringZhejiang UniversityHangzhouPeople’s Republic of China
  2. 2.Oncological Surgery and Cancer Center, The First Affiliated HospitalZhejiang UniversityHangzhouPeople’s Republic of China

Personalised recommendations